{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:52:56Z","timestamp":1766598776993,"version":"3.48.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-5-005"],"award-info":[{"award-number":["2021-I2M-5-005"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bbrep.2025.102249","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T15:16:48Z","timestamp":1757776608000},"page":"102249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Anti-tumor analysis of the RIG-I agonist in vitro and in vivo"],"prefix":"10.1016","volume":"44","author":[{"given":"Qian","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bopei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoqiang","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2025.102249_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/imr.12574","article-title":"Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses","volume":"280","author":"Garg","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbrep.2025.102249_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrep.2025.102249_bib3","doi-asserted-by":"crossref","first-page":"13990","DOI":"10.1128\/JVI.02273-14","article-title":"Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity","volume":"88","author":"Kulkarni","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrep.2025.102249_bib4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.immuni.2011.05.003","article-title":"Immune signaling by RIG-I-like receptors","volume":"34","author":"Loo","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.bbrep.2025.102249_bib5","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1053\/j.gastro.2009.02.066","article-title":"Extracellular and intracellular pattern recognition receptors cooperate in the recognition of Helicobacter pylori","volume":"136","author":"Rad","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbrep.2025.102249_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41423-020-00602-7","article-title":"Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors","volume":"18","author":"Onomoto","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbrep.2025.102249_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8943","article-title":"RIG-I activation is critical for responsiveness to checkpoint blockade","volume":"4","author":"Heidegger","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrep.2025.102249_bib8","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s00262-019-02380-2","article-title":"An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation","volume":"68","author":"Castiello","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrep.2025.102249_bib9","doi-asserted-by":"crossref","first-page":"29007","DOI":"10.18632\/oncotarget.25626","article-title":"Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment","volume":"9","author":"Elion","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrep.2025.102249_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s13238-017-0431-5","article-title":"RIG-I: a multifunctional protein beyond a pattern recognition receptor","volume":"9","author":"Xu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbrep.2025.102249_bib11","article-title":"Molecular Insight into the apoptotic mechanism of cancer cells: an explicative review","volume":"17","author":"Kumar","year":"2024","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.bbrep.2025.102249_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-016-0471-3","article-title":"RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer","volume":"36","author":"Zhu","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2025.102249_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ccr.2013.11.011","article-title":"Hepatic RIG-I predicts survival and interferon-\u03b1 therapeutic response in hepatocellular carcinoma","volume":"25","author":"Hou","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrep.2025.102249_bib14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12935-018-0639-3","article-title":"Decreased RIG-I expression is associated with poor prognosis and promotes cell invasion in human gastric cancer","volume":"18","author":"Chen","year":"2018","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbrep.2025.102249_bib15","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1007\/s00262-023-03483-7","article-title":"The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity","volume":"72","author":"Girone","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrep.2025.102249_bib16","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1084\/jem.20190801","article-title":"Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses","volume":"216","author":"Jiang","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrep.2025.102249_bib17","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00262-022-03191-8","article-title":"Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies","volume":"71","author":"Moreno","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrep.2025.102249_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41392-023-01603-4","article-title":"Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors","volume":"8","author":"Cui","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrep.2025.102249_bib19","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/JVI.79.5.2689-2699.2005","article-title":"Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I","volume":"79","author":"Sumpter","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bbrep.2025.102249_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.trsl.2017.08.004","article-title":"The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy","volume":"190","author":"Wu","year":"2017","journal-title":"Transl. Res."},{"key":"10.1016\/j.bbrep.2025.102249_bib21","article-title":"Targeting innate immunity in cancer therapy","volume":"9","author":"Rameshbabu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.bbrep.2025.102249_bib22","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1084\/jem.20080091","article-title":"Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5","volume":"205","author":"Kato","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrep.2025.102249_bib23","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00595-021-02324-3","article-title":"Systematic review of resectable intraductal tubulopapillary neoplasm with special reference to recurrence patterns","volume":"52","author":"Seki","year":"2022","journal-title":"Surg. Today"},{"key":"10.1016\/j.bbrep.2025.102249_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.09.003","article-title":"Cell competition and tumor heterogeneity","volume":"63","author":"Parker","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbrep.2025.102249_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbcan.2017.03.001","article-title":"A population genetics perspective on the determinants of intra-tumor heterogeneity","volume":"1867","author":"Hu","year":"2017","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrep.2025.102249_bib26","article-title":"Tracking tumor evolution one-cell-at-a-time","volume":"6","author":"Sharma","year":"2019","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.bbrep.2025.102249_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ph9020033","article-title":"Tumor heterogeneity, single-cell sequencing, and drug resistance","volume":"9","author":"Schmidt","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbrep.2025.102249_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/life11121355","article-title":"Immunotherapy for hepatocellular carcinoma: new prospects for the cancer therapy","volume":"11","author":"Fasano","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bbrep.2025.102249_bib29","first-page":"62","article-title":"Breaking boundaries: chronic diseases and the frontiers of immune microenvironments","volume":"1","author":"Li","year":"2025","journal-title":"Media Res."},{"key":"10.1016\/j.bbrep.2025.102249_bib30","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201979","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Kroemer","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrep.2025.102249_bib31","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrep.2025.102249_bib32","article-title":"Recent advances in oncolytic virus therapy for hepatocellular carcinoma","volume":"13","author":"Zhu","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrep.2025.102249_bib33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-023-02309-4","article-title":"Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial","volume":"29","author":"Soliman","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrep.2025.102249_bib34","doi-asserted-by":"crossref","first-page":"11662","DOI":"10.1039\/D5RA00163C","article-title":"Enhancing anti-tumor immunity through intratumoral combination therapy with amphiphilic conjugates of oxaliplatin and imidazoquinoline TLR7\/8 agonist","volume":"15","author":"Verschuere","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bbrep.2025.102249_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216634","article-title":"Oncolytic virus-based combination therapy in breast cancer","volume":"585","author":"Bahreyni","year":"2024","journal-title":"Cancer Lett."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240558082500336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240558082500336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:48:01Z","timestamp":1766598481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240558082500336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"alternative-id":["S240558082500336X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102249","relation":{},"ISSN":["2405-5808"],"issn-type":[{"type":"print","value":"2405-5808"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-tumor analysis of the RIG-I agonist in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102249"}}